What is STASON PHARMACEUTICALS?
Headquartered in the United States, Stason Pharmaceuticals operates as a multifaceted pharmaceutical entity with over 26 years of industry experience. The company distinguishes itself through a robust portfolio that spans oncology, renal care, and orphan drug indications. Beyond its proprietary product development, Stason serves as a vital Contract Development and Manufacturing Organization (CDMO), providing analytical testing and high-potency product production. By maintaining high-containment facilities, the firm addresses the rigorous safety and regulatory requirements necessary for handling potent compounds, while simultaneously diversifying its revenue streams through a growing consumer supplement division and an extensive global distribution network.
How much funding has STASON PHARMACEUTICALS raised?
STASON PHARMACEUTICALS has raised a total of $931K across 2 funding rounds:
Debt
$350K
Debt
$581K
Debt (2020): $350K with participation from PPP
Debt (2021): $581K led by PPP
Key Investors in STASON PHARMACEUTICALS
PPP
Public-Private Partnership
What's next for STASON PHARMACEUTICALS?
With the recent influx of capital, Stason Pharmaceuticals is well-positioned to further optimize its CDMO infrastructure and expand its high-containment manufacturing capabilities. As the pharmaceutical sector faces increasing pressure to localize supply chains and ensure the reliability of complex drug production, Stason's strategic focus on oncology and orphan indications provides a defensive moat. Future growth will likely center on deepening its collaborative partnerships with drug-development firms, leveraging its established analytical testing expertise to capture a larger share of the outsourced manufacturing market. The company's ability to balance generic market presence with specialized, high-barrier-to-entry production services remains a cornerstone of its long-term value proposition in the life sciences sector.
See full STASON PHARMACEUTICALS company page
